OTCMKTS:ROSGQ Rosetta Genomics (ROSGQ) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Rosetta Genomics Stock (OTCMKTS:ROSGQ) Get Rosetta Genomics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume17 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Rosetta Genomics is a molecular diagnostics company that develops and commercializes tests based on microRNA biomarkers for oncology and other disease areas. Leveraging proprietary platforms for microRNA discovery and quantification, the company’s products aim to enhance the accuracy of disease diagnosis, prognosis and therapeutic guidance. Its technology is designed to work with a variety of sample types, including formalin-fixed, paraffin-embedded (FFPE) tissue, blood and fine-needle aspirates, enabling broad clinical applicability. Founded in 2003 and headquartered in Rehovot, Israel, Rosetta Genomics operates a CLIA-certified laboratory in the United States and maintains research and development activities at its Israeli site. The company collaborates with academic centers, medical institutions and pharmaceutical companies to advance microRNA-based biomarker research. Through these partnerships, it seeks to develop companion diagnostics that align targeted therapies with patients most likely to benefit from treatment. Rosetta’s test menu includes assays for various solid tumors, such as lung, colorectal and melanoma cancers, providing clinicians with information to differentiate tumor types and predict patient outcomes. By focusing on microRNA signatures—short, non-coding RNA molecules that regulate gene expression—the company offers a novel approach to biomarker discovery that complements existing genomic and proteomic methods. Rosetta continues to expand its diagnostic pipeline and explore new indications where microRNA profiling may improve clinical decision-making.AI Generated. May Contain Errors. Read More Receive ROSGQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rosetta Genomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ROSGQ Stock News HeadlinesROSGQ Rosetta Genomics Ltd.September 25, 2025 | seekingalpha.com10x Genomics files new EU patent suits against NanoString, VizgenJune 1, 2023 | msn.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. | Porter & Company (Ad)10x Genomics launches big expansion with new Pleasanton officesMay 23, 2023 | msn.comTwist Bioscience Shares Rise 16% After Launch of RNA Sequencing ToolsMay 22, 2023 | marketwatch.comOMICSEDGE FORMS STRATEGIC PARTNERSHIP WITH ALMADEN GENOMICS TO STREAMLINE DRUG DISCOVERYMay 20, 2023 | it.tmcnet.comTelo Genomics to raise $2M through private placement of unitsMay 20, 2023 | msn.comGenomics And Proteomics Reagents, Research Kits And Analytical Instruments Market Share, Analysis, Size, and Forecast 2028May 9, 2023 | marketwatch.comSee More Headlines ROSGQ Stock Analysis - Frequently Asked Questions How do I buy shares of Rosetta Genomics? Shares of ROSGQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/09/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:ROSGQ CIKN/A Webwww.rosettagenomics.com Phone972732220700Fax972-73-222-0701Employees86Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-5.36 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:ROSGQ) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump's Next Move Could Shrink Your DollarThere's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...Priority Gold | SponsoredI’ll Keep This Short… (Huge AI Opportunity)Analyst Ross Givens says the top AI opportunity right now isn't Microsoft, Google, Amazon, Apple, or Nvidia - ...Traders Agency | SponsoredAI Bubble Could Finally Be Done - Wall St's WarningWall Street analysts are warning that the AI-driven market rally may be nearing its limits, with some cautioni...TradeSmith | SponsoredChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rosetta Genomics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rosetta Genomics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.